A Randomized, Double-Blind, Crossover Study on the Pharmacokinetics of a Novel Formulation of CoQ₁₀ With Pyridoxal 5′-Phosphate and Phosphatidyl Choline

REFERENCES

• Alleva R, Tomasetti M, Bompadre S, Littarru P. Oxidation of LDL and their subfractions: kinetic aspects and CoQ10 content. Mol Aspects Med. 1997;18:s105–s112.
   Google Scholar
• Bhagavan HN, Chopra RK. Coenzyme Q10: absorption, tissue uptake, metabolism and pharmacokinetics. Free Rad Res. 2006;40:455–453.
   PubMedGoogle Scholar
• Constantinescu R, McDermott MP, DiCenzo R, Elisabeth A, de Blieck EA, Christopher H, Beal MF, Bednarczyk EM. A randomized study of the bioavailability of different formulations of coenzyme Q10 (ubiquinone). J Clin Pharmacol. 2007;47:1580–1586.
   PubMed Web of Science ®Google Scholar
• Dutton PL, Ohnishi T, Darrouzet E, Leonard, MA, Sharp RE, Cibney BR, Daldal F, Moser CC. 4 coenzyme Q oxidation reduction reactions in mitochondrial electron transport. In: VE Kagan and PJ Quinn (Eds.), Coenzyme Q: Molecular mechanisms in health and disease, pp. 65–82. Boca Raton, FL: CRC Press, 2000.
   Google Scholar
• Elmberger PG, Kalen A, Brunk UT, Dallner G. Discharge of newly-synthesized dolichol and ubiquinone with lipoproteins to rat liver perfusate and to the bile. Lipids 1989;24:919–930.
   PubMed Web of Science ®Google Scholar
• Ernster L, Dallner G. Biochemical, physiological and medical aspects of ubiquinone function. Biochim Biophys Acta. 1995;1271:195–204.
   PubMed Web of Science ®Google Scholar
• Evans M, Baisley J, Barss S, Guthrie N. A randomized, double-blind trial on the bioavailability of two Q10 formulations. J Funct. Foods 2009;1:65–73.
   Web of Science ®Google Scholar
• Ferrante KL, Shefner J, Zhang H, Betensky R, O’Brien M, Yu H, Fantasia M, Taft J, Beal MF, Traynor B, Newhall K, Donofrio P, Caress J, Ashburn C, Freiberg B, O'Neill C, Paladenech C, Walker T, Pestronk A, Abrams B, Florence J, Renna R, Schierbecker J, Malkus B, Cudkowicz M. Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS. Neurology 2005;65:1834–1836.
   PubMed Web of Science ®Google Scholar
• Ghirlanda G, Oradei A, Manto A, Lippa S, Uccioli L, Caputo S, Greco A, Littarru G. Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study. J Clin Pharmacol. 1993;33(3):226–229.
   PubMed Web of Science ®Google Scholar
• Greenberg S, Frishman WH. Co-enzyme Q10: a new drug for cardiovascular disease. J Clin Pharmacol. 1990;30:596–608.
   PubMed Web of Science ®Google Scholar
• Grossi G, Bargossi AM, Fiorella PL, Piazzi S, Battino M, Bianchi GP. Improved high-performance liquid chromatographic method for the determination of coenzyme Q10 in plasma. J Chromatogr. 1992;593:217–226.
   PubMed Web of Science ®Google Scholar
• Kaikkonen J, Tuomainen TP, Nyyssonen K, Salonen JT. Coenzyme Q10: absorption, antioxidative properties, determinants, and plasma levels. Free Radic Res. 2002;36:389–397.
   PubMed Web of Science ®Google Scholar
• Kishi T, Watanabe T, Folkers K. Bioenergetics in clinical medicine XV. Inhibition of coenzyme Q10-enzymes by clinically used adrenergic blockers of beta-receptors. Res Commun Chem Pathol Pharmacol. 1977;17(1):157–164.
   PubMedGoogle Scholar
• Miles MV. The uptake and distribution of coenzyme Q10. Mitochondrion 2007;7(Suppl. 1): S72–S77.
   PubMedGoogle Scholar
• Miles MV, Horn P, Miles L, Tang P, Steele P, DeGrauw T. Bioequivalence of coenzyme Q10 from OTC supplements. Nutr Res. 2002;22:919–929.
   Web of Science ®Google Scholar
• Miles MV, Patterson BJ, Schapiro MB, Hickey FJ, Chalifonte-Evans M, Horn PS, Hotze SL. Coenzyme Q10 absorption and tolerance in children with Downs’ syndrome: a dose-ranging trial. Ped Neurol. 2006;35:30–37.
   Google Scholar
• Mitchell P. The vital protomotive role of coenzyme Q. In: K Folkers, Y Yamamura, GP Littarru (Eds.). Biomedical and clinical aspects of coenzyme Q (Vol 6), (pp. 3–10). Amsterdam, the Netherlands: Elsevier, 1991.
   Google Scholar
• Mortensen SA, Leth A, Agner E, Rohde M. Dose-related decrease of coenzyme Q10 during treatment with HMG-CoA reductase inhibitors. Mol Aspects Med. 1997;18(Suppl.):137–144.
   Google Scholar
• Mosca F, Fattorini D, Bompadre S, Littarru GP. Assay of coenzyme Q10 in plasma by a single dilution step. Anal Biochem. 2002;305:49–54.
   PubMed Web of Science ®Google Scholar
• Nishimukai M, Hara H. Enteral administration of soybean phosphatidylcholine enhances the lymphatic absorption of lycopene, but reduces that of alpha-tocopherol in rats. J Nutr. 2004;134(8):1862–1866.
   PubMedGoogle Scholar
• Ostlund RE, Jr., Spilburg CA, Stenson WF. Sitostanol administered in lecithin micelles potently reduces cholesterol absorption in humans. Am J Clin Nutr. 1999;70(5):826–831.
   PubMed Web of Science ®Google Scholar
• Permanetter B, Rossy W, Klein G, Weingartner F, Seidl KF, Blomer H. Ubiquinone (coenzyme Q10) in the long term treatment of idiopathic dilated cardiomyopathy. Eur Heart J. 1992;13:1528–1533.
   PubMedGoogle Scholar
• Reahal S, Wrigglesworth J. Tissue concentrations of coenzyme Q10 in the rat following its oral and intraperitoneal administration. Drug Metab Dispos. 1992;20:423–427.
   PubMedGoogle Scholar
• Scalori V, Alessandri MG, Giovannini L, Bertelli A. Plasma and tissue concentrations of coenzyme Q10 in the rat after intravenous, oral and topical administrations. Int J Tissue React. 1990;12:149–154.
   PubMedGoogle Scholar
• Strijks E, Kremer HP, Horstink MW. Q10 therapy in patients with idiopathic Parkinson's disease. Mol Aspects Med. 1997;18(Suppl.):S237–S240.
   Google Scholar
• Tomono Y, Hasegawa J, Seki T, Motegi K, Morishita N. Pharmacokinetic study of deuterium-labelled coenzyme Q10 in man. Int J Clin Pharmacol Ther Toxicol. 1986;24:536–541.
   PubMedGoogle Scholar
• Wajda R., Zirkel J, Schaffer T. Increase of bioavailability of coenzyme Q10 and vitamin E. J Med Food 2007;10:731–734.
   PubMed Web of Science ®Google Scholar
• Weis M, Mortensen SA, Rassing MR, Moller-Sonnergaard J, Poulsen G, Rasmussen SN. Bioavailability of four oral coenzyme Q10 formulations in healthy volunteers. Mol Aspects Med. 1994;(15 Suppl.):s273–s280.
   Google Scholar
• Wiela-Hojeńska A, Orzechowska-Juzwenko K. Bioavailability and its significance in pharmacotherapy. Pol Merkur Lekarski. 2003;14(79):89–93.
   PubMedGoogle Scholar
• Willis R, Anthony M, Sun L, Honse Y, Qiao G. Clinical implications of the correlation between coenzyme Q10 and vitamin B6 status. Biofactors 1999;9(2–4):359–363.
   PubMed Web of Science ®Google Scholar